Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Amicus Therapeutics, Inc. (FOLD) - free report >>
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amicus Therapeutics, Inc. (FOLD) - free report >>
Image: Bigstock
Best Momentum Stocks to Buy for October 24th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, October 24:
Amicus Therapeutics, Inc. (FOLD - Free Report) : This biotechnology company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 10% over the last 60 days.
Amicus Therapeutics, Inc. Price and Consensus
Amicus Therapeutics, Inc. price-consensus-chart | Amicus Therapeutics, Inc. Quote
Amicus Therapeutics' shares gained 10.2% over the last three months compared with the S&P 500’s advanced of 6.8%. The company possesses a Momentum Score of A.
Amicus Therapeutics, Inc. Price
Amicus Therapeutics, Inc. price | Amicus Therapeutics, Inc. Quote
Clipper Realty Inc. (CLPR - Free Report) : This real estate company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 43.6% over the last 60 days.
Clipper Realty Inc. Price and Consensus
Clipper Realty Inc. price-consensus-chart | Clipper Realty Inc. Quote
Clipper Realty's shares gained 68.2% over the last three months compared with the S&P 500’s advanced of 6.7%. The company possesses a Momentum Score of B.
Clipper Realty Inc. Price
Clipper Realty Inc. price | Clipper Realty Inc. Quote
Harrow, Inc. (HROW - Free Report) : This eyecare pharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 164.3% over the last 60 days.
Harrow, Inc. Price and Consensus
Harrow, Inc. price-consensus-chart | Harrow, Inc. Quote
Harrow's shares gained 127.2% over the last three months compared with the S&P 500’s advanced of 6.7%. The company possesses a Momentum Score of A.
Harrow, Inc. Price
Harrow, Inc. price | Harrow, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.